Completed PHASE2 INTERVENTIONAL 1-arm NCT00498186

Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)

An Open-label Extension Trial to Determine Safety and Tolerability of Long-term Transdermal Application of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

Sponsor: UCB Pharma

Conditions Restless Legs Syndrome

Interventions Rotigotine

Updated 8 times since 2017 Last updated: Sep 24, 2014 Started: Jul 31, 2003 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Restless Legs Syndrome and is currently completed. UCB Pharma leads this study, which shows 8 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2
Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Pharma

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alzira, Spain , Bamberg, Germany , Barcelona, Spain , Berlin, Germany , Bielefeld, Germany , Gelsenkirchen, Germany , Gera, Germany , Halle, Germany , Innsbruck, Austria , Jena, Germany and 14 more locations